Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801.
Shinobu HosokawaEiki IchiharaDaijiro HaradaShoichi KuyamaKoji InoueKenichi GembaHirohisa IchikawaYuka KatoNaohiro OdaIsao OzeTomoki TamuraToshiyuki KozukiTakahiro UmenoToshio KuboKatsuyuki HottaAkihiro BesshoYoshinobu MaedaKatsuyuki KiuraPublished in: International journal of clinical oncology (2022)
UMIN000030955.